- Home
- ALHC vs HRMY Comparison
ALHC vs HRMY Comparison
Compare ALHC & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALHC | HRMY |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.2B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ALHC | HRMY |
|---|---|---|
| Price | $12.98 | $38.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $23.13 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 5.7M | 731.2K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | 7.97 |
| EPS | 0.22 | ★ 1.84 |
| Revenue | ★ $3,948,719,000.00 | $868,453,000.00 |
| Revenue This Year | $33.69 | $19.75 |
| Revenue Next Year | $24.74 | $12.88 |
| P/E Ratio | $58.77 | ★ $20.69 |
| Revenue Growth | ★ 46.06 | 21.51 |
| 52 Week Low | $12.70 | $25.52 |
| 52 Week High | $25.12 | $40.87 |
Technical Indicators
Market Signals| Indicator | ALHC | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 34.04 | 53.78 |
| Support Level | $13.09 | $37.12 |
| Resistance Level | $22.62 | $39.40 |
| Average True Range (ATR) | 0.65 | 1.33 |
| MACD | 0.06 | -0.08 |
| Stochastic Oscillator | 27.75 | 42.69 |
Price Performance
Historical ComparisonAbout ALHC Alignment Healthcare Inc.
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.